# Marker Therapeutics, Inc.: financial statements, quarterly

MRKR · Nasdaq · CIK 1094038 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/mrkr.md) · [Financials](/companies/mrkr/financials.md) · [Filings](/companies/mrkr/filings.md) · [Insiders](/companies/mrkr/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/mrkr/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [258](/filings/0001410578-24-001978.md) | [1,057 d](/filings/0001410578-25-000549.md) | [1,244](/filings/0001410578-25-001342.md) | [1,169](/filings/0001410578-25-001826.md) | [1,926](/filings/0001104659-25-111502.md) | [2,252 d](/filings/0001104659-26-031274.md) | [349](/filings/0001104659-26-062763.md) | [861](/filings/0001410578-25-001826.md) | [1,233](/filings/0001104659-25-111502.md) | [1,103 d](/filings/0001104659-26-031274.md) | [752](/filings/0001104659-26-062763.md) | not reported |
| Research and development | $k | [2,045](/filings/0001410578-24-001978.md) | [2,617 d](/filings/0001410578-25-000549.md) | [2,575](/filings/0001410578-25-001342.md) | [2,335](/filings/0001410578-25-001826.md) | [3,471](/filings/0001104659-25-111502.md) | [5,086 d](/filings/0001104659-26-031274.md) | [3,135](/filings/0001104659-26-062763.md) | [4,177](/filings/0001104659-26-097262.md) | [2,346](/filings/0001104659-25-111502.md) | [2,141 d](/filings/0001104659-26-031274.md) | [2,843](/filings/0001104659-26-062763.md) | [1,476](/filings/0001104659-26-097262.md) |
| Operating income | $k | [(3,200)](/filings/0001410578-24-001978.md) | [(2,938) d](/filings/0001410578-25-000549.md) | [(2,549)](/filings/0001410578-25-001342.md) | [(2,308)](/filings/0001410578-25-001826.md) | [(2,400)](/filings/0001104659-25-111502.md) | [(3,861) d](/filings/0001104659-26-031274.md) | [(4,958)](/filings/0001104659-26-062763.md) | [(5,122)](/filings/0001104659-26-097262.md) | [(2,137)](/filings/0001104659-25-111502.md) | [(1,884) d](/filings/0001104659-26-031274.md) | [(4,073)](/filings/0001104659-26-062763.md) | [(2,620)](/filings/0001104659-26-097262.md) |
| Net income | $k | [(2,982)](/filings/0001410578-24-001978.md) | [(2,803) d](/filings/0001410578-25-000549.md) | [(2,393)](/filings/0001410578-25-001342.md) | [(2,193)](/filings/0001410578-25-001826.md) | [(2,308)](/filings/0001104659-25-111502.md) | [(3,838) d](/filings/0001104659-26-031274.md) | [(4,446)](/filings/0001104659-26-062763.md) | [(4,016)](/filings/0001104659-26-097262.md) | [(1,999)](/filings/0001104659-25-111502.md) | [(1,703) d](/filings/0001104659-26-031274.md) | [(3,179)](/filings/0001104659-26-062763.md) | [(1,826)](/filings/0001104659-26-097262.md) |
| Diluted EPS | $ per share | [(0.34)](/filings/0001410578-24-001978.md) | not reported | [(0.27)](/filings/0001410578-25-001342.md) | [(0.25)](/filings/0001410578-25-001826.md) | [(0.26)](/filings/0001104659-25-111502.md) | not reported | [(0.40)](/filings/0001104659-26-062763.md) | [(0.29)](/filings/0001104659-26-097262.md) | [(0.12)](/filings/0001104659-25-111502.md) | not reported | [(0.16)](/filings/0001104659-26-062763.md) | [(0.09)](/filings/0001104659-26-097262.md) |
| Basic EPS | $ per share | [(0.34)](/filings/0001410578-24-001978.md) | not reported | [(0.27)](/filings/0001410578-25-001342.md) | [(0.25)](/filings/0001410578-25-001826.md) | [(0.26)](/filings/0001104659-25-111502.md) | not reported | [(0.40)](/filings/0001104659-26-062763.md) | [(0.29)](/filings/0001104659-26-097262.md) | [(0.12)](/filings/0001104659-25-111502.md) | not reported | [(0.16)](/filings/0001104659-26-062763.md) | [(0.09)](/filings/0001104659-26-097262.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [17.5](/filings/0001410578-23-002307.md) | [15.1](/filings/0001410578-25-000549.md) | [11.3](/filings/0001410578-24-000865.md) | [7.8](/filings/0001410578-24-001454.md) | [9.0](/filings/0001410578-24-001978.md) | [19.2](/filings/0001104659-26-031274.md) | [13.7](/filings/0001410578-25-001342.md) | [10.5](/filings/0001410578-25-001826.md) | [17.6](/filings/0001104659-25-111502.md) | [16.1](/filings/0001104659-26-097262.md) | [14.9](/filings/0001104659-26-062763.md) | [11.3](/filings/0001104659-26-097262.md) |
| Current assets | $m | [19.5](/filings/0001410578-23-002307.md) | [17.1](/filings/0001410578-25-000549.md) | [14.1](/filings/0001410578-24-000865.md) | [11.7](/filings/0001410578-24-001454.md) | [10.9](/filings/0001410578-24-001978.md) | [22.0](/filings/0001104659-26-031274.md) | [17.0](/filings/0001410578-25-001342.md) | [14.8](/filings/0001410578-25-001826.md) | [21.7](/filings/0001104659-25-111502.md) | [19.1](/filings/0001104659-26-097262.md) | [17.4](/filings/0001104659-26-062763.md) | [14.6](/filings/0001104659-26-097262.md) |
| Total assets | $m | [19.5](/filings/0001410578-23-002307.md) | [17.1](/filings/0001410578-25-000549.md) | [14.1](/filings/0001410578-24-000865.md) | [11.7](/filings/0001410578-24-001454.md) | [10.9](/filings/0001410578-24-001978.md) | [22.0](/filings/0001104659-26-031274.md) | [17.0](/filings/0001410578-25-001342.md) | [14.8](/filings/0001410578-25-001826.md) | [21.7](/filings/0001104659-25-111502.md) | [19.1](/filings/0001104659-26-097262.md) | [17.4](/filings/0001104659-26-062763.md) | [14.6](/filings/0001104659-26-097262.md) |
| Current liabilities | $m | [2.8](/filings/0001410578-23-002307.md) | [3.1](/filings/0001410578-25-000549.md) | [2.3](/filings/0001410578-24-000865.md) | [2.0](/filings/0001410578-24-001454.md) | [3.5](/filings/0001410578-24-001978.md) | [3.5](/filings/0001104659-26-031274.md) | [2.5](/filings/0001410578-25-001342.md) | [4.3](/filings/0001410578-25-001826.md) | [3.3](/filings/0001104659-25-111502.md) | [2.3](/filings/0001104659-26-097262.md) | [3.6](/filings/0001104659-26-062763.md) | [2.4](/filings/0001104659-26-097262.md) |
| Total liabilities | $m | [2.8](/filings/0001410578-23-002307.md) | [3.1](/filings/0001410578-25-000549.md) | [2.3](/filings/0001410578-24-000865.md) | [2.0](/filings/0001410578-24-001454.md) | [3.5](/filings/0001410578-24-001978.md) | [3.5](/filings/0001104659-26-031274.md) | [2.5](/filings/0001410578-25-001342.md) | [4.3](/filings/0001410578-25-001826.md) | [3.3](/filings/0001104659-25-111502.md) | [2.3](/filings/0001104659-26-097262.md) | [3.6](/filings/0001104659-26-062763.md) | [2.4](/filings/0001104659-26-097262.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [16.7](/filings/0001410578-24-001978.md) | [14.1](/filings/0001104659-26-031274.md) | [11.8](/filings/0001410578-25-001826.md) | [9.7](/filings/0001104659-25-111502.md) | [7.4](/filings/0001104659-25-111502.md) | [18.6](/filings/0001104659-26-097262.md) | [14.5](/filings/0001104659-26-097262.md) | [10.5](/filings/0001104659-26-097262.md) | [18.4](/filings/0001104659-25-111502.md) | [16.8](/filings/0001104659-26-097262.md) | [13.8](/filings/0001104659-26-097262.md) | [12.2](/filings/0001104659-26-097262.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Current portion of debt: not reported
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,127) d](/filings/0001410578-24-001978.md) | [(2,368) d](/filings/0001410578-25-000549.md) | [(3,837)](/filings/0001410578-25-001342.md) | [(3,568) d](/filings/0001410578-25-001826.md) | [1,197 d](/filings/0001104659-25-111502.md) | [(4,703) d](/filings/0001104659-26-031274.md) | [(5,500)](/filings/0001104659-26-062763.md) | [(1,878) d](/filings/0001104659-26-097262.md) | [(2,736) d](/filings/0001104659-25-111502.md) | [(1,900) d](/filings/0001104659-26-031274.md) | [(1,404)](/filings/0001104659-26-062763.md) | [(3,716) d](/filings/0001104659-26-097262.md) |
| Capital expenditure | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [8.4](/filings/0001410578-23-002307.md) | [8.7](/filings/0001410578-24-000865.md) | [8.8](/filings/0001410578-24-001454.md) | [8.8](/filings/0001410578-24-001978.md) | [8.9](/filings/0001410578-25-001342.md) | [8.9](/filings/0001410578-25-001826.md) | [8.9](/filings/0001104659-25-111502.md) | [11.1](/filings/0001104659-26-062763.md) | [14.0](/filings/0001104659-26-097262.md) | [16.8](/filings/0001104659-25-111502.md) | [19.3](/filings/0001104659-26-062763.md) | [19.3](/filings/0001104659-26-097262.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 16,673,127 at 2026-08-07, from the cover of the [10-Q filed 2026-08-14](/filings/0001104659-26-097262.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:33 ET. No prices; not investment advice.